Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1173-1176

  Reger, Thomas S ^a   Zunic, Jasmine ^a   Stock, Nicholas ^a   Wang, Bowei ^a   Smith, Nicholas D ^a   Munoz, Benito ^a   Green, Mitchell D ^a   Gardner, Michael F ^a   James, Joyce P ^a   Chen, Weichao ^a   Alves, Kenneth ^a   Si, Qian ^a   Treonze, Kelly M ^a   Lingham, Russell B ^a   Mumford, Richard A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; CYTOCHROME P450 3A4; DIPEPTIDE; ESTER; HETEROARYLAMINE; HETEROCYCLIC COMPOUND; HYDROXYPROLINE METHYL ESTER; PIPERIDINE; PIPERIDINE DERIVATIVE; PRODRUG; PROLINE DERIVATIVE; PROLINE DIPEPTIDE; PROTEIN INHIBITOR; TERTIARY AMINE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 4 RECEPTOR; VLA 4 ANTAGONIST; PROLINE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ARTICLE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG INHIBITION; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHEMISTRY; COMPARATIVE STUDY; METABOLISM; PHYSIOLOGY;

ANIMALS; BINDING, COMPETITIVE; DIPEPTIDES; HETEROCYCLIC COMPOUNDS; HUMANS; INTEGRIN ALPHA4BETA1; PROLINE; PROTEIN BINDING; RATS;

EID: 74049161233     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.009     Document Type: Article

References (23)

1. Hemler M.E., Elices M.J., Parker C., and Takada Y. Immunol. Rev. 114 (1990) 45
2. Elices M.J. Curr. Opin. Anti-inflam. Immun. 1 (1999) 15
3. Gearing A.J.H., and Newman W. Immunol. Today 14 (1993) 506
4. Hemler M.E. Annu. Rev. Immunol. 8 (1990) 365
5. Abraham W.M., Ahmed A., Sielczak M.W., Narita M., Arrhenius T., and Elices M.J. Am. J. Resp. Crit. Care Med. 156 (1997) 696
6. Koo G.C., Shah K., Ding G.J., Xiao J., Wnek R., Doherty G., Tong X.C., Pepinsky R.B., Lin K.C., Hagmann W.K., Kawka D., and Singer I.I. Am. J. Respir. Crit. Care Med. 167 (2003) 1400
7. Seiffge D. J. Rheum. 23 (1996) 2086
8. Pedolsky D., Lobb R.R., King N., Benjamin C., Pepinsky R.B., Sehgal P., and deBeaumont M. J. Clin. Invest. 92 (1993) 372
9. Leone D.R., Giza K., Gill A., Dolinski B.M., Yang W., Perper S., Scott D.M., Lee W.C., Cornebise M., Wortham K., Nickerson-Nutter C., Chen L.L., LePage D., Spell J.C., Whalley E.T., Petter R.C., Adams S.P., Lobb R.R., and Pepinsky R.B. J. Pharmacol. Exp. Ther. 305 (2003) 1150
10. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., and O'Connor P.W.N. Engl. J. Med. 348 (2003) 15
11. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., Panaccione R., Sanders M., Schreiber S., Targan S., van Deventer S., Goldblum R., Despain D., Hogge G.S., and Rutgeerts P.N. N. Engl. J. Med. 353 (2005) 1912
12. Doherty G.A., Yang G.X., Borges E., Tong S., McCauley E.D., Treonze K.M., Van Riper G., Pacholok S., Si Q., Koo G.C., Shah K., Mumford R.A., and Hagmann W.K. Bioorg. Med. Chem. Lett. 13 (2003) 1891
13. Hagmann W.K. Curr. Top. Med. Chem. 4 (2004) 1461
14. Venkatraman S., Lebsack A.D., Alves K., Gardner M.F., James J., Lingham R.B., Maniar S., Mumford R.A., Si Q., Stock N., Treonze K.M., Wang B., Zunic J., and Munoz B. Bioorg. Med. Chem. Lett. 19 (2009) 5803
15. Lin L.S., Lanza Jr. T., Jewell J.P., Liu P., Jones C., Kieczykowski G.R., Treonze K., Si Q., Manior S., Koo G., Tong X., Wang J., Schuelke A., Pivnichny J., Wang R., Raab C., Vincent S., Davies P., MacCoss M., Mumford R.A., and Hagmann W.K. J. Med. Chem. 52 (2009) 3449
16. Riley R.J., Grime K., and Weaver R. Expert Opin. Drug Metab. Toxicol. 3 (2007) 51
17. Bensoussan C., Delaforge M., and Mansuy D. Biochem. Pharmacol. 49 (1995) 591
18. -1.
19. For discussions on the regioselectivity of 1,2,4-triazole and tetrazole alkylation, see:. Bulger P.G., Cottrell I.F., Cowden C.J., Davies A.J., and Dolling U.-H. Tetrahedron Lett. 41 (2000) 1297
20. Ulhaq S., Chinje E.C., Naylor M.A., Jaffar M., Stratford I.J., and Threadgill M.D. Bioorg. Med. Chem. Lett. 6 (1998) 2139
21. We have previously demonstrated that this class of compounds generally has a higher affinity for the activated state of VLA-4. Thus, potency was examined only against the resting state of VLA-4 to best differentiate compounds.
22. 125I]-tracer shown below was utilized to assess binding potency, receptor off-rate, and rat receptor occupancy. A detailed description of each of these experiments was recently provided in the Supplementary data of Ref. 8.{A figure is presented}
23. Treonze K.M., Alves K., Fischer P., Hagmann W.K., Hora D., Kulick A., Vakerich K., Smith N.D., Lingham R.B., Maniar S., Reger T.S., Zunic J., Munoz B., Prasit P., Nicholson D., Si Q., Judd K., Nicolich S., Kellerhouse P., Thompson D., and Mumford R.A. Vet. Immun. Immunopath. 130 (2009) 79